Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci-Reference-Cited by-同舟云学术

Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci

Published:2019-09 Issue:9 Volume:87 Page:
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Kalfopoulou Ermioni¹^ORCID,Laverde Diana¹,Miklic Karmela²,Romero-Saavedra Felipe¹,Malic Suzana²,Carboni Filippo³,Adamo Roberto³,Lenac Rovis Tihana²,Jonjic Stipan²,Huebner Johannes¹

Affiliation:

1. Division of Paediatric Infectious Diseases, Dr. von Hauner Children’s Hospital, Ludwig Maximilians University, Munich, Germany

2. Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

3. GSK, Siena, Italy

Abstract

Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species.

Funder

European Commission

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.00276-19

Reference56 articles.

1. Division of the genus Enterococcus into species groups using PCR-based molecular typing methods

2. Enterococcal infections: host response, therapeutic, and prophylactic possibilities

3. Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance